These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 8243040)
1. In vitro activity of ampicillin, amoxicillin, ampicillin-sulbactam, and amoxicillin-clavulanic acid against consecutive clinical isolates of Enterobacteriaceae. Fuchs PC; Barry AL; Pfaller MA; Hardy DJ; McLaughlin JC; Gerlach EH Diagn Microbiol Infect Dis; 1993; 17(2):171-5. PubMed ID: 8243040 [TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases. Gatermann S; Marre R Infection; 1991; 19(2):106-9. PubMed ID: 1646771 [TBL] [Abstract][Full Text] [Related]
3. [A comparison of the in vitro susceptibility of three bacteria to beta-lactamase inhibitors and to ampicillin and cefazolin]. Acar N; Diri MC; Türkyilmaz FR Mikrobiyol Bul; 1987 Oct; 21(4):284-8. PubMed ID: 3332705 [TBL] [Abstract][Full Text] [Related]
4. [Comparison of the in vitro activity of amoxycillin + clavulanic acid and ampicillin + sulbactam combinations against 50 Haemophilus influenzae strains producing beta lactamase]. Moittie D; Simonet M; Veron M Pathol Biol (Paris); 1989 May; 37(5):390-3. PubMed ID: 2789362 [TBL] [Abstract][Full Text] [Related]
5. Beta-lactamase inhibitors and Acinetobacter spp. Eng RH; Smith SM; Cherubin CE J Antimicrob Chemother; 1990 Sep; 26(3):449-51. PubMed ID: 2172200 [No Abstract] [Full Text] [Related]
6. [Errors of the agar diffusion method to predict Escherichia coli's susceptibility to ampicillin-sulbactam and amoxicillin-clavulanic acid]. Villar HE; Jugo MB; Fernández-Lausi A; Farinati AE Enferm Infecc Microbiol Clin; 1996 May; 14(5):308-10. PubMed ID: 8744371 [TBL] [Abstract][Full Text] [Related]
7. Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae. Pfaller M; Barry A; Fuchs P; Gerlach E; Hardy D; McLaughlin J Eur J Clin Microbiol Infect Dis; 1993 Mar; 12(3):200-5. PubMed ID: 8389705 [TBL] [Abstract][Full Text] [Related]
8. [In vitro comparison of the beta lactamase-inhibitory action of clavulanic acid and sulbactam in ampicillin-resistant enterobacteria]. Grimm H Arzneimittelforschung; 1987 Oct; 37(10):1116-9. PubMed ID: 3501722 [TBL] [Abstract][Full Text] [Related]
9. Correlation of in vitro susceptibility testing results for amoxicillin-clavulanate and ampicillin-sulbactam using a panel of beta-lactamase-producing Enterobacteriaceae. Siu LK; Cheng WL; Ho PL; Ng WS; Chau PY; Lo JY APMIS; 1998 Sep; 106(9):917-20. PubMed ID: 9808419 [TBL] [Abstract][Full Text] [Related]
10. Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypes. Oliver A; Pérez-Vázquez M; Martínez-Ferrer M; Baquero F; De Rafael L; Cantón R Antimicrob Agents Chemother; 1999 Apr; 43(4):862-7. PubMed ID: 10103192 [TBL] [Abstract][Full Text] [Related]
11. [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro]. Blahová J; Hupková M; Krcméry V Cas Lek Cesk; 1995 Sep; 134(17):558-61. PubMed ID: 7553760 [TBL] [Abstract][Full Text] [Related]
12. Implications of beta-lactamase-inhibitor combinations. Fuchs PC; Barry AL J Reprod Med; 1990 Mar; 35(3 Suppl):317-21. PubMed ID: 2319514 [TBL] [Abstract][Full Text] [Related]
13. In-vitro sensitivity of amoxicillin/clavulanic acid (Augmentin) to isolated beta-lactamases and in-vitro antibacterial activity. Esposito S; Noviello S J Chemother; 1990 Jun; 2(3):167-70. PubMed ID: 2380766 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of in vitro methods for testing susceptibility of anaerobes to ampicillin-sulbactam and amoxicillin-clavulanic acid. Fuchs PC; Barry AL; Jones RN J Clin Microbiol; 1988 Jun; 26(6):1246-7. PubMed ID: 3384939 [TBL] [Abstract][Full Text] [Related]
15. Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination. Jones RN; Barry AL J Clin Microbiol; 1987 Oct; 25(10):1920-5. PubMed ID: 3117843 [TBL] [Abstract][Full Text] [Related]
16. Possible prevention of in vitro selection of resistant Streptococcus pneumoniae by beta-lactamase inhibitors. Carsenti-Etesse H; Durant J; De Salvador F; Bensoussan M; Bensoussan F; Pradier C; Bernard E; Mondain V; Thabaut A; Dellamonica P Eur J Clin Microbiol Infect Dis; 1994 Dec; 13(12):1058-62. PubMed ID: 7889969 [TBL] [Abstract][Full Text] [Related]
17. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin. Aronoff SC; Jacobs MR; Johenning S; Yamabe S Antimicrob Agents Chemother; 1984 Oct; 26(4):580-2. PubMed ID: 6097169 [TBL] [Abstract][Full Text] [Related]
18. Interpretive criteria for susceptibilities of Haemophilus influenzae to ampicillin, amoxicillin, and amoxicillin-clavulanic acid. Fuchs PC; Barry AL J Clin Microbiol; 1994 Nov; 32(11):2846-50. PubMed ID: 7852584 [TBL] [Abstract][Full Text] [Related]
19. In vitro activity of YTR 830. Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029 [TBL] [Abstract][Full Text] [Related]
20. [Combined antibacterial activity of clavulanic acid with amoxicillin and ampicillin against Gram-negative strains]. Mascellino MT; Prignano G; Lorenzi A; Iegri F; Martorano E; Catania S; Ginanni Corradini S Boll Ist Sieroter Milan; 1984; 63(5):447-52. PubMed ID: 6335660 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]